Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. (ESLA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
esla · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Estrella Immunopharma, Inc. (ESLA) measures how much investors pay for each dollar of the company's trailing earnings. ESLA's current PE ratio of N/A is calculated by dividing its stock price of $1.13 by its TTM earnings per share of -$0.31.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2021 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Estrella Immunopharma, Inc.You ESLA | $49M | N/A | — | -$0.31 |
 Anebulo Pharmaceuticals, Inc. ANEB | $15M | N/A | — | -$0.25 |
 Atossa Therapeutics, Inc. ATOS | $39M | N/A | — | -$4.04 |
 eXoZymes, Inc. EXOZ | $73M | N/A | — | -$1.09 |
 Greenwich LifeSciences, Inc. GLSI | $318M | N/A | — | -$1.43 |
 Immix Biopharma, Inc. IMMX | $428M | N/A | — | -$0.89 |
 Oncolytics Biotech Inc. ONCY | $84M | N/A | — | -$0.41 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.35 | — | |
2024-12-31 FY2024 | — | $-0.24 | — | |
2024-06-30 FY2024 | — | $-0.21 | — | |
2022-12-31 FY2022 | — | $-0.17 | — | |
2022-06-30 FY2022 | — | $-0.29 | — | |
2021-06-30 FY2021 | — | $-0.02 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Estrella Immunopharma, Inc. (ESLA) measures how much investors pay for each dollar of the company's trailing earnings. ESLA's current PE ratio of N/A is calculated by dividing its stock price of $1.13 by its TTM earnings per share of -$0.31.
Frequently asked questions
ESLA pe ratio · 6 questionsESLA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.13 and TTM EPS of -$0.31. Data sourced from Financial Modeling Prep via ESLA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Estrella Immunopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09